Surgical Robots Industry Explained: The U.S. View
Robotic surgery lets surgeons operate through small incisions using robotic arms they control from a console. The U.S. market is led by Intuitive, maker of the da Vinci system, and its business model explains the industry: the robot is the entry ticket, but most money comes afterward, from instruments and accessories used in every procedure and from service contracts. In the second quarter of 2026 Intuitive's revenue rose 19% to $2.89 billion; instruments and accessories brought in $1.73 billion, about 60% of the total, while system sales were $685 million. Worldwide procedures grew about 16%, with da Vinci procedures up about 15% and its Ion lung-biopsy system up about 36%. The company placed 468 da Vinci systems, 246 of them the newest da Vinci 5, lifting the installed base 12% to 11,710. It expects da Vinci procedures to grow about 13.5–15.5% in 2026. Growth depends on hospitals' capital budgets, surgeon training and proof that robotic procedures improve outcomes or efficiency; tariffs add about 1 point of cost to Intuitive's gross margin.
- Procedures
- Intuitive: worldwide procedures up about 16% in Q2 2026
- Installed base
- da Vinci installed base 11,710 systems, up 12%, at June 30, 2026
- Recurring
- Instruments and accessories about 60% of Intuitive's Q2 2026 revenue
How the chain works
Intuitive revenue mix, Q2 2026
| Revenue | What drives it | |
|---|---|---|
| Instruments and accessories | $1.73B, up 18% | Number of procedures |
| Systems | $685M, from $575M | Hospital capital budgets, new models |
| Service | $472M, up about 21% | Installed base |
| Total | $2.89B, up 19% | Procedures up about 16% |
The razor-and-blades model
Hospitals buy or lease a robot, then pay for instruments and accessories every time it is used, plus service. In Intuitive's second quarter of 2026, according to its July 16 release, instruments and accessories brought in $1.73 billion, up 18%, about 60% of total revenue of $2.89 billion, while systems brought in $685 million, up from $575 million.
Because most revenue follows procedures, the installed base and how often each robot is used matter more than any single quarter's system sales. Intuitive's da Vinci installed base reached 11,710 systems at June 30, 2026, up 12% from 10,488 a year earlier.
Procedures and new systems
Worldwide procedures on da Vinci and Ion grew about 16% in the second quarter of 2026: da Vinci about 15% and Ion, used for lung biopsies, about 36%. Intuitive placed 468 da Vinci systems, up from 395, including 246 da Vinci 5 systems, its newest model, up from 180, and 55 Ion systems.
For 2026 Intuitive expects da Vinci procedures to grow about 13.5–15.5%, near the midpoint. New models encourage hospitals to upgrade, and new procedure types expand the market.
Costs, tariffs and competition
Intuitive expects a non-GAAP gross margin of 68–69% of revenue in 2026, including an estimated 1.0 percentage point impact from tariffs. Its quarterly filing says U.S. import tariffs and any reciprocal measures may raise the cost of materials and finished goods imported from outside the U.S.
Growth also depends on hospital finances: robots are a capital purchase, and hospitals justify them through surgeon demand, patient outcomes and efficiency. Competitors are entering with their own systems, which could pressure prices over time.
How the U.S. view differs from the China view
The Chinese version of this page looks at Chinese makers of surgical robots that are winning domestic approvals, competing on price and benefiting from policies favoring local equipment in hospitals.
From the U.S. side the market is led by an American company whose installed base keeps growing worldwide, and the key measures are procedure growth and recurring revenue. Competition from local makers makes China a harder market for U.S. companies.
2026: procedures keep compounding
In the second quarter of 2026 Intuitive's worldwide procedures grew about 16%, and its installed base grew 12% to 11,710 da Vinci systems.
Instruments and accessories, which follow procedures, made up about 60% of revenue, while system placements rose to 468, more than half of them the new da Vinci 5.
Even with tariff costs of about 1 point of gross margin, a growing installed base means steady recurring revenue.
- Recurring instrument revenue follows procedures, not system sales.
- New system generations drive upgrades in the installed base.
- Tariffs and hospital budgets are the main near-term pressures.
Common misreadings
MythRobot makers mostly earn money selling robots.
RealityInstruments and accessories were about 60% of Intuitive's Q2 2026 revenue.
MythRobotic surgery growth is slowing to a crawl.
RealityIntuitive expects da Vinci procedures up about 13.5–15.5% in 2026.
MythThe market is saturated.
RealityIntuitive placed 468 da Vinci systems in Q2 2026, up from 395.
MythMedtech is immune to tariffs.
RealityIntuitive expects tariffs to cost about 1 point of gross margin in 2026.
Hospitals, competition and policy: scenarios
| Scenario | Main effect | How it passes through |
|---|---|---|
| Hospital budgets tighten | System sales | Fewer placements, procedures still grow |
| New procedure types adopted | Procedure volume | More instrument revenue |
| Competitors gain approvals | Pricing | Pressure on system and instrument prices |
| Tariffs rise | Margins | Higher costs |
| Outcome data favor robotics | Adoption | More surgeons trained and using robots |
| Upgrade cycle to new models | System revenue | Higher placements |
Supply and demand by segment
| Segment | Supply rigidity | Concentration | New demand | Policy role | What to watch |
|---|---|---|---|---|---|
| Robot systems | High (approvals, engineering) | Very high | Yes | High (FDA clearance) | Placements |
| Instruments and accessories | Medium | Very high | Yes | Medium | Procedure growth |
| Service | Low | Very high | Yes | Low | Installed base |
| Hospital adoption | Medium (training) | Low | Yes | Medium (reimbursement) | Utilization |
Supply rigidity: how long new capacity takes and whether money can speed it up. Concentration: whether output sits in a few countries or companies. The more rigid and concentrated, the more prone to shortages.
How to track it
| Indicator | What it tells you | Where to find it |
|---|---|---|
| Procedure growth | Underlying demand | Intuitive quarterly releases, free |
| Systems placed and installed base | Future recurring revenue | Intuitive quarterly releases, free |
| Tariff and margin guidance | Cost pressure | Intuitive guidance, free |
| FDA clearances for competitors | Competition | FDA device databases, free |
Sources
- Intuitive: second quarter 2026 earnings (2026-07-16)
- Intuitive: Form 10-Q for the quarter ended June 30, 2026
Last updated 2026-10-18.